News and Announcements
Proteomics International’s PromarkerD Test Latest Comprehensive Update
- Published April 04, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Proteomics International Laboratories Ltd (ASX: PIQ) (PILL), the leader in predictive diagnostics for diabetic kidney disease, presents a comprehensive update on the commercialisation progress for its PromarkerD test.
KEY TAKEAWAYS:
- PromarkerD rated the world’s leading diagnostic test for diabetic kidney disease by global market research firm Frost & Sullivan;
- First licensing income received;
- Key patents secured and extended;
- Clinical laboratory prototype manufacture on target for mid-2017;
- First commercial sales are targeted for the end of 2017;
- Validation study completed – announcement of results pending publication of the prior predictive development study;
- Development study shows PromarkerD correctly predicts 95% of otherwise healthy diabetics who will develop chronic kidney disease;
- Discussions continue with prospective diagnostic companies in the USA, China, Europe, Australia and Japan to secure licences for the commercialisation of PromarkerD.
PromarkerD is a predictive diagnostic test for diabetic kidney disease. In a clinical study PromarkerD correctly predicted 95% of otherwise healthy diabetics who went on to develop chronic kidney disease within four years. PromarkerD was last month rated the world’s leading diagnostic test for diabetic kidney disease in the Frost & Sullivan report Biomarkers Enabling Diabetes and Obesity Management.
Company Updates
Dogs First to Reduce Risk: QBiotics’ Smarter Path to Oncology Markets
QBiotics took a compound derived from a north Queensland rainforest tree all the way to veterinary registration before pursuing human oncology to de-risk its human cancer programme. Interim CEO Ebru Davidson argues that sequence – now backed by early responses across several human cancers – is the company’s real asset. The story that pulled Wholesale […]
Built on discipline, not complexity: inside an ASX equities income strategy
Haydn Froggatt and Zac Brabin have decades of derivatives experience between them and access to almost any strategy in the market. They use two of the simplest structures available, and wrote 202 positions with them last year. Published by Fairway Capital Management. Based on an interview with co-founders Haydn Froggatt and Zac Brabin. Two traders, […]
BlackRock has named the next Economy. What this latest paper means for Private Market Investors.
BlackRock has put a name on something the smart money has been circling for two years. Its digital assets research team calls it the machine-native economy. The thesis fits in one line. AI is machine-native intelligence. Digital assets are machine-native money. Both are built on the same architecture, and they are converging into a single […]
Backed By Leading Investment Groups and Family Offices
